Clinical Trials Logo

Metastatic Breast Cancer clinical trials

View clinical trials related to Metastatic Breast Cancer.

Filter by:
  • Active, not recruiting  
  • « Prev · Page 9

NCT ID: NCT01084863 Active, not recruiting - Clinical trials for Metastatic Breast Cancer

Evaluate Safety, Efficacy and Pharmacokinetics

Compare
Start date: February 2010
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of the study is to demonstrate equivalent pharmacokinetics (PK)

NCT ID: NCT01009788 Active, not recruiting - Breast Cancer Clinical Trials

ABT-888 and Temozolomide for Metastatic Breast Cancer and BRCA1/2 Breast Cancer

Start date: November 2009
Phase: Phase 2
Study type: Interventional

The purpose of this research study is to find out if the combination of ABT-888 and temozolomide is safe and effective in treating patients with metastatic breast cancer. ABT-888 works by obstructing a DNA enzyme called poly (ADP-ribose) polymerase (PARP) which helps repair cancer cells damaged by chemotherapy. By blocking the PARP enzyme, the cancer cells are unable to repair themselves and as a result die. The other drug in this study is temozolomide. Temozolomide is designed to damage DNA in order to prevent cancer cells from reproducing. Because PARP inhibitors, such as ABT-888, prevent cancer cells from repairing their own DNA, they enhance the potential of chemotherapy therapy like temozolomide to induce cell death. The combination of ABT-888 and temozolomide has been used in a clinical trial for treatment of other cancers and information for this research study suggests that the combination may help to inhibit growth in breast cancer. ONLY THE EXPANSION COHORT BELOW IS RECRUITING: BRCA CARRIER EXPANSION COHORT: The purpose of the expansion cohort is to further evaluate the activity and safety of this combination in BRCA mutation carriers with metastatic breast cancer.

NCT ID: NCT00986661 Active, not recruiting - Clinical trials for Hepatocellular Carcinoma

A Study to Assess PV-10 Chemoablation of Cancer of the Liver

Start date: October 2009
Phase: Phase 1
Study type: Interventional

This open-label study will evaluate the safety, tolerability, pharmacokinetics and effect on tumor growth following a single intralesional injection of PV-10 in subjects with either (a) hepatocellular carcinoma (HCC) that is not amenable to resection, transplant or other potentially curative therapy or (b) cancer metastatic to the liver.

NCT ID: NCT00912938 Active, not recruiting - Clinical trials for Metastatic Breast Cancer

Evaluate the Relationship of Bone Remodeling Markers for Skeletal Complications in Metastatic Breast Cancer Patients

Start date: December 2007
Phase: Phase 4
Study type: Interventional

to evaluate whether bone marker can provide the valuable predictor of skeletal complications and whether regular assessing of NTX(N-telopeptide of type I collagen) and osteocalcin can be useful in advanced breast cancer patients with bone metastasis receiving zoledronic acid.

NCT ID: NCT00431704 Active, not recruiting - Clinical trials for Metastatic Breast Cancer

VinCaT: Vinorelbine, Carboplatin and Trastuzumab in Advanced Her-2 Positive Breast Cancer

VinCaT
Start date: October 2007
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the activity and safety of the combination of vinorelbine, carboplatin and trastuzumab in HER2-positive metastatic breast cancer.

NCT ID: NCT00262067 Active, not recruiting - Clinical trials for Metastatic Breast Cancer

A Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy in Untreated Metastatic Breast Cancer (RIBBON 1)

Start date: December 2005
Phase: Phase 3
Study type: Interventional

This is a Phase III, multicenter, randomized, placebo-controlled trial designed to evaluate the efficacy and safety of bevacizumab in combination with chemotherapy compared with chemotherapy alone in subjects with previously untreated metastatic breast cancer.

NCT ID: NCT00248287 Active, not recruiting - Clinical trials for Metastatic Breast Cancer

PhII ICb With/Without Erbitux in MBC Pts

CA225200
Start date: July 28, 2005
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the objective response rates produced by irinotecan and carboplatin therapy with or without Erbitux in patients with Metastatic Breast Cancer.